China’s Market Slide Puts Corporate Power on Display

Chinese shares fell into bear-market territory as state-backed funds intervened to stem losses, while investors and companies faced sharply diverging results. The CSI 300 Index dropped 20 per cent from a June high; the Star Market 50 gauge lost about 40 per cent from its June record. The intervention came after the slide, with no quick rebound in sight.

Who Has the Power

Morgan Stanley said Chinese onshore and offshore stocks could fall another 10 to 15 per cent before bottoming out, based on valuations during several market troughs since 2008. The investment bank said a quick rebound was unlikely because conditions had intensified “negative momentum.” UBS Group also said sentiment was unlikely to recover soon, though it saw limited potential for further declines.

Those forecasts put the market’s direction in the hands of institutional investors and analysts whose assessments can shape expectations. Their language is measured; the losses are not. Chinese stocks were among the world’s worst-performing major markets that month, amid an uneven economic recovery and the unwinding of artificial-intelligence bets. State-backed funds tried to stem the decline, placing public financial power into a market still marked by falling valuations.

The numbers identify the pressure on stocks, but not who ultimately bears each loss. The source gives no breakdown of individual investors’ holdings or losses. What it does show is a system in which market trouble prompts intervention by state-backed funds, while large financial institutions pronounce on how much further prices might fall.

A Toy Boom Meets the Market

Pop Mart, the Chinese toymaker known for Labubu collectible dolls, reported a 45 to 50 per cent year-on-year decline in third-quarter revenue. Overseas operations and online channels bore the brunt as sales weakened across major markets. Mainland China revenue fell 25 to 30 per cent from a year earlier.

The contraction was steeper elsewhere. Revenue in Asia-Pacific markets outside mainland China and Oceania dropped 65 to 70 per cent. The Americas fell 70 to 75 per cent, while Europe and other regions declined 50 to 55 per cent. Pop Mart reported the figures in a business update filed with the Hong Kong stock exchange late Tuesday. Investors were questioning the long-term demand for the dolls.

That is the corporate scoreboard: a steep revenue drop, divided by region, and investors weighing whether demand will last. The figures show where sales weakened; they don't say how the decline affects workers or customers. The market's judgment arrives in percentages all the same.

One Company Rises While Another Falls

Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, reported third-quarter revenue up 20.55 per cent to 8.95 billion yuan (US$1.34 billion), above analyst estimates of 8.55 billion yuan. Net profit for the three months ended September 30 reached 2.46 billion yuan, up 88.92 per cent year on year and above the Bloomberg analyst consensus estimate of 2.38 billion yuan.

The company said in a Tuesday filing that improving innovative-drug sales and out-licensing revenue contributed to the growth. Pop Mart’s regional sales fell sharply; Hengrui’s revenue and profit climbed. The contrast is plain in the filings, and so is the hierarchy of this account: institutions and investors set the terms of market judgment, while state-backed funds step in when losses deepen. No grassroots response, mutual-aid effort, election, or legislative remedy appears in the reported facts.